CDC42BPG — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4135600	0.78	2/20
SCHEMBL2650684	0.75	2/20
SCHEMBL6465326	0.74	2/20
SCHEMBL4553131	0.70	2/20
SCHEMBL7231228	0.70	2/20
SCHEMBL2648503	0.70	2/20
SCHEMBL2649542	0.70	2/20
SCHEMBL4551864	0.70	2/20
SCHEMBL7249555	0.70	2/20
SCHEMBL19857269	0.70	2/20
SCHEMBL21169981	0.70	2/20
SCHEMBL2649978	0.66	2/20
SCHEMBL19868852	0.66	2/20
SCHEMBL2650680	0.66	2/20
SCHEMBL13497841	0.65	2/20
SCHEMBL19857273	0.65	2/20
SCHEMBL4553479	0.63	2/20
SCHEMBL8486792	0.62	2/20
SCHEMBL4569577	0.62	2/20
SCHEMBL9196324	0.61	2/20

Clinical trials — most relevant to CDC42BPG by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study	PHASE4	COMPLETED
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Phase II Dasatinib Study in Advanced Breast Cancer	PHASE2	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Evaluation of the Changes in Matrix Metalloproteinase-9 Levels With Salvadora Persica (Miswak) in Periodontal Fibroblasts and Gingival Crevicular Fluid in Patients With Periodontitis	EARLY_PHASE1	NOT_YET_RECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Role of Chemokine and Chemokine Receptor in Psoriasis	nan	WITHDRAWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Pulsed Electro Magnetic Fields (PEMF) in Depression	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Immune Cell Response to Stimuli	nan	RECRUITING
Identification of an Asthma Susceptibility Gene on 3P	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CDC42BPG binder may also engage these)

Protein	Name	Similarity
Q80UW5	—	1.000	Q80UW5 →
Q80XI6	—	0.992	Q80XI6 →
Q8C2K1	—	0.991	Q8C2K1 →
P58660	—	0.991	P58660 →
Q9JIR0	—	0.991	Q9JIR0 →
Q9BWT7	—	0.989	Q9BWT7 →
Q66HA1	—	0.989	Q66HA1 →
P97680	—	0.989	P97680 →
Q921Q7	—	0.989	Q921Q7 →
P54265	—	0.989	P54265 →
Q99ML2	—	0.988	Q99ML2 →
Q9BXL6	—	0.988	Q9BXL6 →
Q8WWN8	—	0.987	Q8WWN8 →
TNK1	Non-receptor tyrosine-protein kinase TNK1	0.987	landscape →
Q99KF0	—	0.987	Q99KF0 →
Q96P48	—	0.987	Q96P48 →
RIN1	Ras and Rab interactor 1 (Ras inhibitor JC99)	0.987	landscape →
Q9H4E7	—	0.987	Q9H4E7 →
Q6ZVH7	—	0.987	Q6ZVH7 →
B3EX63	—	0.987	B3EX63 →
Q8BXP5	—	0.986	Q8BXP5 →
A4FUG8	—	0.986	A4FUG8 →
Q9BRR9	—	0.986	Q9BRR9 →
Q5TJE5	—	0.986	Q5TJE5 →
O75064	—	0.986	O75064 →
D2H0G5	—	0.986	D2H0G5 →
Q96HA7	—	0.986	Q96HA7 →
Q924T7	—	0.986	Q924T7 →
Q9BYX2	—	0.986	Q9BYX2 →
Q4LDD4	—	0.986	Q4LDD4 →